Capricor Shares Surge on FDA Review of Duchenne Drug Amendment

Capricor Therapeutics shares surged more than 60 percent on Friday after the company announced the U.S. Food and Drug Administration is willing to review new data for its experimental Duchenne muscular dystrophy drug, deramiocel, potentially extending the regulatory review timeline.